APLS Stock Analysis: Buy, Sell, or Hold?
APLS - Apellis Pharmaceuticals, Inc. Common Stock
$41.03
-0.03 (-0.07%)
âŧ
5d:
-0.22%
30d:
+0.44%
90d:
+83.91%
WAIT
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When APLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: APLS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: APLS is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: APLS is currently trading at $41.03, which is considered fair based on recent price action. From a valuation perspective, the stock is trading at a discount (Forward PE: -187.9) compared to its historical average (480.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, APLS is in a strong uptrend. The price is currently testing key support at $40.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, APLS is in a strong uptrend. The price is currently testing key support at $40.93. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
50/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($40.93)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$40.93
Resistance Level
$41.14
Current Trend
Strong Uptrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-187.95
Wall Street Target
$40.93
(-0.2%)
Revenue Growth (YoY)
60.9%
Profit Margin
12.1%
PE vs Historical
-188.0 vs 480.9
CHEAP
Share & Embed Analysis
Last updated: August 27, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 38 SELL |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 40 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 29 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 48 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 49 HOLD |
